Episode
Ep. 307 Germline & Somatic Testing in Prostate Cancer Therapy with Dr. Tanya Dorff and Dr. Evan Yu
- Podcast
- BackTable Urology
- Published
- Jun 9, 2026
- Duration seconds
- 2451
- Processing state
not_requested- Canonical source
- https://traffic.megaphone.fm/BTL2198738428.mp3
Actions
POST https://stenobird.com/v1/public/podcasts/backtable-urology-3724776/episodes/ep-307-germline-somatic-testing-in-prostate-cancer-therapy-with-dr-tanya-dorff-and-dr-evan-yu/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/backtable-urology-3724776/ep-307-germline-somatic-testing-in-prostate-cancer-therapy-with-dr-tanya-dorff-and-dr-evan-yu.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Can you really treat prostate cancer effectively without knowing the genetics? In this episode of BackTable Urology, Dr. Evan Yu and Dr. Tanya Dorff join host Dr. Alan Tan to discuss why genetic testing is essential in personalized prostate cancer care. They discuss when and how to perform germline and somatic testing, address common barriers, and share best practices for counseling patients. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Pfizer. --- Timestamps 00:00 - Introduction02:18 - Who Gets Somatic Testing?06:43 - Patient Barriers to Testing09:00 - Genetic Testing Workflow12:28 - Treating BRCA2 Alterations24:18 - Monitoring Progression: ctDNA vs. PSA vs. Imaging29:32 - Treating mCRPC with ATM Mutations34:39 - CDK12 Classification 37:43 - Closing Takeaways --- More about this episode The doctors explore how BRCA2 and other DNA repair alterations can directly shape treatment decisions, focusing on the roles of PARP inhibitors and platinum therapy in advanced cases. The discussion highlights why both germline and somatic testing are critical for identifying actionable mutations and discuss the nuances of interpreting test results, including current limitations and emerging biomarkers. They also examine challenges such as insurance coverage, patient misconceptions, and workflow integration, as well as the movement toward truly personalized, biology-driven approaches in prostate cancer care. --- Resources Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial:https://pmc.ncbi.nlm.nih.gov/articles/PMC12705445/ Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-28…